Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 19/20 | 0.68 |
| ▸ | PPARA | Q07869 | 17/20 | 0.68 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4057645 | 1.00 | PPARG (0.68) | PPARGPPARAFFAR1 | |
| SCHEMBL6157774 | 1.00 | PPARG (0.68) | PPARGPPARAFFAR1 | |
| SCHEMBL6156648 | 0.91 | PPARG (0.66) | PPARGPPARAFFAR1 | |
| SCHEMBL6157590 | 0.91 | PPARG (0.66) | PPARGPPARAFFAR1 | |
| SCHEMBL6156644 | 0.91 | PPARG (0.66) | PPARGPPARAFFAR1 | |
| SCHEMBL6158389 | 0.87 | PPARG (0.72) | PPARGPPARAFFAR1 | |
| SCHEMBL7832391 | 0.87 | PPARG (0.72) | PPARGPPARAFFAR1 | |
| SCHEMBL6158396 | 0.87 | PPARG (0.72) | PPARGPPARAFFAR1 | |
| SCHEMBL4054572 | 0.85 | PPARG (0.75) | PPARGPPARAFFAR1 | |
| SCHEMBL4054575 | 0.85 | PPARG (0.75) | PPARGPPARAFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6677363-B1 | ADMINISTERING PIOGLITAZONE OR SALT, OXIME INSULIN SENSITIZER, FK-614, KRP-297, AND 5-((6-(2-FLUOROBENZYLOXY)-2-NAPHTHYL)METHYL)-2,4-THIAZOLIDINEDIONE TO TREAT DIABETES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2004-01-13 | — | — | US | claimed |
| US-7595333-B2 | Agent for improving acidosis | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-29 | — | — | US | disclosed |
| US-20050239854-A1 | Body weight gain inhibitors | SUGIYAMA YASUO | 2005-10-27 | — | — | US | disclosed |
| US-6924300-B2 | Oxyiminoalkanoic acid derivatives | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2005-08-02 | — | — | US | disclosed |
| EP-1077957-B1 | OXYIMINOALKANOIC ACID DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2004-08-04 | — | — | EP | disclosed |
| EP-1428531-A1 | Oxyiminoalkanoic acid derivatives with hypoglycemic and hypolipidemic activity | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2004-06-16 | — | — | EP | disclosed |
| US-20040106649-A1 | Agent for improving acidosis | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-06-03 | — | — | US | disclosed |
| US-20040077689-A1 | Abc expression promoters | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-22 | — | — | US | disclosed |
| EP-1382336-A1 | ABC EXPRESSION PROMOTERS | Takeda Chemical Industries, Ltd. (JP) | 2004-01-21 | — | — | EP | disclosed |
| US-20030186985-A1 | Oxyiminoalkanoic acid derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-10-02 | — | — | US | disclosed |
| US-20030134884-A1 | Neovascularization inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-07-17 | — | — | US | disclosed |
| EP-1304121-A1 | BODY WEIGHT GAIN INHIBITORS | Takeda Chemical Industries, Ltd. (JP) | 2003-04-23 | — | — | EP | disclosed |
| EP-1277730-A1 | NEOVASCULARIZATION INHIBITORS | Takeda Chemical Industries, Ltd. (JP) | 2003-01-22 | — | — | EP | disclosed |
| US-6495581-B1 | DRUG FOR TREATING DIABETES MELLITUS, HYPERLIPEMIA, IMPAIRED GLUCOSE TOLERANCE, ARTERIAL SCLEROSIS AND IMPROVING INSULIN RESISTANCE, INFLAMMATORY DISEASE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-12-17 | — | — | US | disclosed |
| EP-1169037-A2 | USE OF INSULIN SENSITISERS FOR IMPROVING KETOSIS | Takeda Pharmaceutical Company Limited (JP) | 2002-01-09 | — | — | EP | disclosed |
| US-6251926-B1 | OXYIMINOALKANOIC ACID DERIVATIVES HAVING HYPOGLYCEMIC EFFECT AND HYPOLIPIDEMIC EFFECT, IS USEFUL FOR TREATMENT OF DIABETES MELLITUS, HYPERLIPEMIA, IMPAIRED GLUCOSE TOLERANCE INFLAMMATORY DISEASE AND ARTERIOSCLEROSIS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-06-26 | — | — | US | disclosed |
| EP-1077957-A1 | OXYIMINOALKANOIC ACID DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY | Takeda Chemical Industries, Ltd. (JP) | 2001-02-28 | — | — | EP | disclosed |
| WO-2000061127-A2 | USE OF INSULIN SENSITISERS FOR IMPROVING KETOSIS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-10-19 | — | — | WO | disclosed |
| WO-1999058510-A1 | OXYIMINOALKANOIC ACID DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186985-A1 | Oxyiminoalkanoic acid derivatives | GPR119, IRS1, CPT1A | PPARG 401/4885PPARA 152/4885FFAR1 53/4885 |
| US-20040077689-A1 | Abc expression promoters | SREBF1, SREBF2, ABCB4 | PPARG 189/4885PPARA 355/4885FFAR1 1498/4885 |
| US-20050239854-A1 | Body weight gain inhibitors | PPARG, GPR119, PPARA | PPARG 1/4885PPARA 3/4885FFAR1 43/4885 |
| US-20040106649-A1 | Agent for improving acidosis | GPR119, SLC2A8, SLC2A1 | PPARG 422/4885PPARA 326/4885FFAR1 77/4885 |
| US-20030134884-A1 | Neovascularization inhibitors | VEGFA, FLT1, FLT4 | PPARG 1641/4885PPARA 1383/4885FFAR1 3421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.